{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:12:18Z","timestamp":1776309138771,"version":"3.50.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Tuberculosis Program of Niger"},{"name":"National Referral laboratory of Niamey"},{"DOI":"10.13039\/100018370","name":"Institute of Tropical Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Outcomes of retreatment for rifampicin-resistant tuberculosis (RR-TB) are rarely reported. We report \u2018definitive outcomes\u2019 after a cascade approach to RR-TB treatment. After a bacteriologically adverse outcome for the 9-months fluoroquinolone-based Short Treatment Regimen (STR), patients were retreated with a bedaquiline-based regimen (BDQ-regimen).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A Retrospective cohort study of RR-TB patients treated with the STR during 2012\u20132019 and retreated with a BDQ-regimen in case of failure or relapse was conducted. Definitive relapse-free cure took into account BDQ-regimen outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 367 patients treated with the STR, 20 (5.4%) experienced failure or relapse. Out of these 20 patients, 14 started a BDQ-regimen, of whom none experienced failure or relapse. Definitive end of treatment outcomes of STR after revising with third-line BDQ-regimen outcomes, 84.7% (311\/367) were cured relapse-free, 10.6% (39\/367) died during treatment and 3.0% (11\/367) were lost to follow-up during treatment with either the STR or BDQ-regimen. Six patients (1.6%; 6\/367) with STR failure\/relapse died before starting a BDQ-regimen. No patient had definitive treatment failure or relapse and remained without treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>If fluoroquinolone resistance is excluded or rare, it is beneficial to use fluoroquinolone as the core drug for a first RR-TB treatment regimen and to safeguard bedaquiline for those in need of retreatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/inthealth\/ihac016","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T12:29:11Z","timestamp":1647433751000},"page":"258-264","source":"Crossref","is-referenced-by-count":8,"title":["Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9645-1994","authenticated-orcid":false,"given":"Mahamadou Bassirou","family":"Souleymane","sequence":"first","affiliation":[{"name":"Damien Foun , TB-MR, BP: 1065 Niamey , Niger"},{"name":"dation Niger , TB-MR, BP: 1065 Niamey , Niger"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Decroo","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine, Unit of Mycobacteriology , Nationalestraat 155, 2000 Antwerp , Belgium"},{"name":"Research Foundation Flanders , 1000 Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa\u00efdou","family":"Mamadou","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Abdou Moumouni de Niamey , Facult\u00e9 des Sciences de la Sant\u00e9, BP: 237 Niamey , Niger"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alphazazi","family":"Soumana","sequence":"additional","affiliation":[{"name":"Programme National de Lutte contre la Tuberculose , Coordination, BP: 613 Niamey , Niger"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim Mamane","family":"Lawan","sequence":"additional","affiliation":[{"name":"Damien Foun , TB-MR, BP: 1065 Niamey , Niger"},{"name":"dation Niger , TB-MR, BP: 1065 Niamey , Niger"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assiatou","family":"Gagara-Issoufou","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Abdou Moumouni de Niamey , Facult\u00e9 des Sciences de la Sant\u00e9, BP: 237 Niamey , Niger"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Adehossi","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Abdou Moumouni de Niamey , Facult\u00e9 des Sciences de la Sant\u00e9, BP: 237 Niamey , Niger"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimer","family":"Ortu\u00f1o-Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Damien Foundation Brussels, TB-MR, Boulevard L\u00e9opold II 263 , 1081 Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutgarde","family":"Lynen","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine, Unit of Mycobacteriology , Nationalestraat 155, 2000 Antwerp , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leen","family":"Rigouts","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine, Unit of Mycobacteriology , Nationalestraat 155, 2000 Antwerp , Belgium"},{"name":"University of Antwerp , Biomedical Sciences, Prinsstraat 13, 2000 Antwerp , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bouke Catherine","family":"de Jong","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine, Unit of Mycobacteriology , Nationalestraat 155, 2000 Antwerp , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armand","family":"Van Deun","sequence":"additional","affiliation":[{"name":"Independent Consultant , 3000 Leuven , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Piubello","sequence":"additional","affiliation":[{"name":"Damien Foun , TB-MR, BP: 1065 Niamey , Niger"},{"name":"dation Niger , TB-MR, BP: 1065 Niamey , Niger"},{"name":"Damien Foundation Brussels , TB-MR, Boulevard L\u00e9opold II 263, 1081 Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"2023050215493485700_bib1","author":"World Health Organization","year":"2021","journal-title":"Global Tuberculosis Report 2021"},{"key":"2023050215493485700_bib2","author":"World Health Organization","year":"2016","journal-title":"WHO Treatment Guidelines for Drug-Resistant Tuberculosis"},{"issue":"55","key":"2023050215493485700_bib3","first-page":"1","article-title":"Short-course regimen for multidrug-resistant tuberculosis:\u202fa decade of evidence","volume":"9","author":"Tr\u00e9bucq","year":"2020","journal-title":"J Clin Med"},{"key":"2023050215493485700_bib4","doi-asserted-by":"crossref","first-page":"105844","DOI":"10.1016\/j.rmed.2019.105844","article-title":"Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements","volume":"161","author":"Piubello","year":"2020","journal-title":"Respir Med"},{"key":"2023050215493485700_bib5","volume-title":"WHO consolidated guidelines on MDR tuberculosis treatment","author":"World Health Organization","year":"2019"},{"issue":"2","key":"2023050215493485700_bib6","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/S2213-2600(19)30473-4","article-title":"Tuberculosis treatment: One-shot approach or cascade of regimens?","volume":"8","author":"Decroo","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2023050215493485700_bib7","doi-asserted-by":"crossref","first-page":"2002250","DOI":"10.1183\/13993003.02250-2020","article-title":"High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss","volume":"57","author":"Souleymane","year":"2021","journal-title":"Eur Respir J"},{"issue":"3","key":"2023050215493485700_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5588\/ijtld.17.0660","article-title":"Principles for constructing a tuberculosis treatment regimen: The role and definition of core and companion drugs","volume":"22","author":"Van Deun","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2023050215493485700_bib9","volume-title":"ANRS scale to grade the severity of adverse events in adults","author":"Agence nationale fran\u00e7aise de recherche sur le sida et les hepatites virales","year":"2003"},{"issue":"3","key":"2023050215493485700_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","article-title":"Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: A multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial","volume":"7","author":"von Groote-Bidlingmaier","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2023050215493485700_bib11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.pulmoe.2021.02.006","article-title":"Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: results from a large global cohort","volume":"27","author":"Koirala","year":"2021","journal-title":"Pulmonology"},{"key":"2023050215493485700_bib12","doi-asserted-by":"crossref","first-page":"e3563","DOI":"10.1093\/cid\/ciaa1894","article-title":"Safety and effectiveness of an all-oral, bedaquiline-based, shorter treatment regimen for rifampicin-resistant tuberculosis in high human immunodeficiency virus (HIV) burden rural South Africa: A retrospective cohort analysis","author":"Tack","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"21","key":"2023050215493485700_bib13","first-page":"1","article-title":"Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: A cross-sectional and longitudinal study","volume":"3099","author":"Ismail","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"2023050215493485700_bib14","doi-asserted-by":"crossref","first-page":"1902383","DOI":"10.1183\/13993003.02383-2019","article-title":"Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients","volume":"55","author":"Nimmo","year":"2020","journal-title":"Eur Respir J"},{"issue":"10","key":"2023050215493485700_bib15","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"}],"container-title":["International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/inthealth\/article-pdf\/15\/3\/258\/50170589\/ihac016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/inthealth\/article-pdf\/15\/3\/258\/50170589\/ihac016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T15:50:03Z","timestamp":1683042603000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/inthealth\/article\/15\/3\/258\/6568500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,4,14]]},"published-print":{"date-parts":[[2023,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/inthealth\/ihac016","relation":{},"ISSN":["1876-3413","1876-3405"],"issn-type":[{"value":"1876-3413","type":"print"},{"value":"1876-3405","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5]]},"published":{"date-parts":[[2022,4,14]]}}}